Leukemia Clinical Trials
A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 41 clinical trials
Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 03418: A Phase 1 First in Human Open Label Dose Escalation Study of AMV564 a CD33 x CD3 Tandem Diabody in Patients with Relapsed or Refractory Acute Myeloid Leukemia
(Amphivena) is studying an investigational drug called AMV564, which may help to treat acute myeloid leukemia (AML). The purpose of this clinical research study is to find the highest tolerable dose that can be given to patients with AML, and to recommend a dose to be used in future studies.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 13418: A Multicenter Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia
The purposes of this study are to see if the study drugs, venetoclax and gilteritinib can be safely and effectively combined for the treatment of patients with acute myeloid leukemia (AML) that has returned after prior treatment, or has failed to respond to prior treatment and identify potential biomarkers.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC#01409: Lintuzumab-Ac225 in Older Patients with Untreated AML
This is a phase 1/2 study of a radio-labeled investigational drug, 225Ac-lintuzumab, given in combination with low-dose cytarabine in previously untreated elderly patients with AML. Phase 1 will establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside, and Phase 2 will help determine the …
- 0 views
- 08 May, 2025
- 1 location
Cardiovascular function in leukemia patients: an observational prospective study
In the last decade, both the incidence and the survival of acute leukemia has been increasing. Therefore, detection of associated illnesses is important. We have recently observed that patients with acute leukemia treated with anthracyclines develop a high rate of symptomatic heart failure.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 44419: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 04717: Phase I open label dose-escalation study to evaluate the safety expansion persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor) administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL)
The main aims of this study are to test the safety of up to 4 different doses of UCART19, and to identify the best dose of UCART19, by measuring what has happened to the leukemia cells at day 28 (28 days after the administration of UCART19), day 84 (84 days …
- 0 views
- 19 Feb, 2024
- 1 location
2 march edit9
This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …
- 0 views
- 19 Feb, 2024
- 1 location
Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) alone and when co-administered with humanized Anti-CD19 Chimeric Antigen Receptor Redirected T cells (huCART19) In Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
This is a single center, single arm, open-label Phase 1 study with two cohorts to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
- 0 views
- 19 Feb, 2024
- 1 location
4march upen 16
This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …
- 0 views
- 19 Feb, 2024